Skip to main content

NPF Endorsed Features

Melissa Weiss, Associate Editor, Lauren Mateja, Managing Editor
Several breakthrough studies and prominent clinical guidelines related to psoriasis were published in 2019. Review some of the most impactful psoriasis content published this year.
Melissa Weiss, Associate Editor
The American Academy of Dermatology and National Psoriasis Foundation released new guidelines on the use of phototherapy for the treatment of psoriasis. Joel Gelfand, MD, MSCE, discussed the updated guidelines with The Dermatologist.
Peter Sonnenreich; Bassem Wolley; and Katherine Moody, Contributing Writers
Certain comorbidities—particularly congestive heart failure, tuberculosis, and HIV infection—can affect the type of psoriasis treatment physicians recommend to their patients.
Melissa Weiss, Associate Editor
Access restrictions to therapies among patients with rheumatoid arthritis and psoriatic arthritis can significantly impact treatment effectiveness and adherence. Natalie Boytsov, PhD, discussed the implications of these restrictions with The Dermatologist.
Melissa Weiss, Associate Editor
Dermatologists have another weapon in their arsenal to prescribe for patients with mild plaque psoriasis.
Peter Sonnenreich; Bassem Wolley; and Linda Geisler, Contributing Writers
The palmoplantar form of psoriasis affects roughly a quarter of those with moderate to severe symptoms and presents unique treatment challenges.
Steve Bieler, National Psoriasis Foundation Staff Writer
The National Psoriasis Foundation is collaborating in a real-world trial evaluating the safety and effectiveness of home vs office phototherapy with the goals of providing important data for this therapeutic option and supporting patient-centered research. Dermatology practices can volunteer to act as clinical sites.
Wasim Haidari, BS, BA, and Steven R. Feldman, MD, PhD
Although these drugs frequently are highly effective at treating psoriasis, prescribing them is only half the battle. Dermatologists and patients both face other challenges to access.
Peter Sonnenreich, Bassem Wolley, Katherine Moody, and Linda Geisler; Contributing Writers
About 30% of patients with psoriasis will develop this chronic, inflammatory comorbidity. Knowing how to recognize and treat it can help improve patient outcomes.
Melissa Weiss, Associate Editor
Recommendations include best practices for addressing noncutaneous aspects associated with psoriasis.
Back to Top